o a collection of information unless it contains a valid OMB control number. Application Number 10560439

Filing Date 2005-12-13 INFORMATION DISCLOSURE First Named Inventor GUTSOL STATEMENT BY APPLICANT Art Unit ( Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number DREX-1004US

		Remove				
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear
	1	4801435		1989-01-31	туцко	
	2	5374802		1994-12-20	DORFMAN	
	3	5437250		1995-08-01	RABINOVICH	
	4	5847353		1998-12-08	TITUS	
	5	5887554		1999-03-30	COHN	
	6	5993761		1999-11-30	CZERNICHOWSKI	
	7	6007742		1999-12-28	CZERNICHOWSKI	
	8	6245309		2001-06-12	ETIEVANT	

		Application Number			10560439							
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			Filing Date			2005-12-13						
			First Named Inventor GUT		TSOL.							
			Art Ur	Art Unit								
			Examiner Name									
				Attorney Docket Number			DREX-1004US	DREX-1004US				
				_								
	_		_			-						_
	9	6322757		2001-1	1-27	COHN						
	10	6363716		2002-0	4-02	BALKO						
	11	6396213		2002-0	5-28	KOLOC						
	12	5425332		1995-0	6-20	RABINO	лсн					
If you wish to add additional U.S. Patent citation			n inform	ation pl	ease click	the a	Add button.		Add			
			U.S.P.	ATENT	APPLI	CATION P	UBL	ICATIONS		Remove		
Examiner Cite   Publication Number   Kind   Code1			Publication Date		Name of Patentee or Applicant of cited Document Pages, Columns, Line Relevant Passages or Figures Appear							
	1											
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n informati	on p	lease click the Ad	button	Add		
				FOREIG	SN PAT	ENT DOC	UMI	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>				n	Name of Patente Applicant of cited Document	or v	vhere Rel	or Relevant	76
	1											П

If you wish to add additional Foreign Patent Document citation information please click the Add button

publisher, city and/or country where published.

NON-PATENT LITERATURE DOCUMENTS [Remove]
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

Τs

Initials\*

Examiner Cite

No

	Application Number		10560439
INFORMATION DIGGI COURT	Filing Date		2005-12-13
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	GUT	SOL
(Not for submission under 37 CFR 1.99)	Art Unit		
(,	Examiner Name		
	Attorney Docket Numb	er	DREX-1004US

1	ΙП
	_

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at twent/LEPTO\_GOV or MPEP 901.94. \* Enter office that issued the document, by the hor-left code (WIPO Standard ST3.). \* For Legarnese patent document, the ordication of the year of the region of the Emperor may precede the sent annumber of the patent document.

\*\*And of document by the appropriate symbols as endicated on the document under WIPO Standard ST.16 if possole, \*\*Applicant is to place a check mark here if Emploit language retriation is altached.\*\*

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10560439
Filing Date		2005-12-13
First Named Inventor GUTS		SOL
Art Unit		
Examiner Name		
Attorney Docket Number		DREX-1004US

### CERTIFICATION STATEMENT

Diagra can	37 CFR	1 97 and	1.98 to make the	e annronniate	coloction(c)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

## ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/KEVIN J. DUNLEAVY/	Date (YYYY-MM-DD)	2006-05-17
Name/Print	KEVIN J. DUNLEAVY	Registration Number	32024

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.